The biological rationale is compelling. Diabetes and heart failure are tightly intertwined: chronically elevated glucose, insulin resistance, and metabolic inflammation damage the heart muscle and blood vessels, causing many patients to progress rapidly from silent cardiac dysfunction to overt, symptomatic heart failure. Epidemiological analyses, including the Atherosclerosis Risk in Communities study, have shown that diabetes accelerates the progression of heart failure, and meta-analyses confirm a substantially elevated risk of new-onset and recurrent heart failure in people with diabetes. Yet heart failure remains notoriously under-recognized in this population; a systematic review published in the Journal of Cardiac Failure documented how frequently the condition is misdiagnosed, often because early symptoms are vague or attributed to other causes.

NT-proBNP—N-terminal pro-B-type natriuretic peptide—is a fragment of a hormone precursor released by heart muscle cells when they are stretched or under pressure. Because the peptide is cleared by the kidneys and is more stable in blood than its cousin BNP, it has become the workhorse biomarker for cardiac stress. Decades of evidence, from the International Collaborative of NT-proBNP study to the Heinz Nixdorf Recall Study, show that elevated concentrations predict cardiovascular events and death, and that NT-proBNP outperforms BNP for predicting first cardiovascular events in the general population. In people with diabetes, serial measurements in trials such as EXAMINE and large biobank analyses from Hong Kong have demonstrated that the biomarker sharply improves prediction of cardiorenal complications, including in patients without any known cardiac disease.

The pivotal shift came when the American Diabetes Association formally endorsed biomarker screening for Stage B heart failure—the asymptomatic phase of cardiac dysfunction defined in the universal classification of heart failure. Under the ADA Standards of Care, measurement of natriuretic peptides is now recommended to identify people with diabetes whose hearts are already straining silently, opening a window for intervention with modern cardioprotective therapies before irreversible damage occurs. Landmark randomized trials underpin this approach: the STOP-HF trial in Ireland showed that natriuretic peptide-based screening combined with collaborative care reduced incident heart failure, while the PONTIAC trial in Austria demonstrated similar benefit in diabetic patients without prior cardiac disease. More recently, the STRONG-DH pilot study tested a risk-based screening and treatment pathway guided by NT-proBNP in diabetes.

What makes the new review distinctive is its pragmatic focus on implementation rather than discovery. The expert panel, convened to share real-world experience, concluded that no single blueprint will work everywhere. Instead, any national or regional early detection program must weigh four parameters: the patient pathway from screening to diagnosis and treatment; the availability of laboratory and specialist resources; the educational needs of frontline clinicians who must interpret and act on test results; and cost-effectiveness within local payment systems. The authors emphasize that a multipronged approach with a clear evaluation, diagnosis, and treatment pathway is essential for NT-proBNP programs to take root globally.

Country-specific experiences illustrate both the promise and the friction of implementation. Consensus statements have emerged from professional societies in Portugal, Switzerland, and Spain, each tailoring screening populations and biomarker thresholds to local epidemiology and health system capacity. In India, real-world data from a tertiary care center demonstrated the feasibility of occult heart failure screening with NT-proBNP in type 2 diabetes, while Irish investigators have documented the prevalence and trajectory of elevated natriuretic peptides in high-risk diabetic populations. In Slovenia, educational initiatives have updated cardiologists and diabetologists on the value of the biomarker, and in the United States, institutional guidelines such as the University of Michigan health system’s protocol for adults with diabetes over fifty show how electronic medical records can embed screening into routine diabetes visits.

The review also confronts the interpretive subtleties that can derail screening programs. NT-proBNP concentrations are influenced by age, sex, renal function, atrial fibrillation, and obesity, and chronic kidney disease—a frequent diabetes complication—can raise levels independently of cardiac status. Studies comparing diagnostic accuracy in chronic kidney disease, quantifying the effect of renal dysfunction on BNP and NT-proBNP ratios, and examining obesity’s impact on diagnostic cut-offs all underscore that thresholds must be fine-tuned rather than applied mechanically. The panel argues that this fine-tuning of the population in scope and the biomarker interpretation thresholds is precisely what will determine whether screening programs are sustainable.

Economics, the panel stresses, may ultimately decide adoption. A series of cost-effectiveness analyses spanning the United States, Brazil, Hong Kong, and China have evaluated whether NT-proBNP-guided screening pays for itself by preventing expensive hospitalizations and advanced disease. Early results suggest that identifying Stage B heart failure and initiating guideline-directed medical therapy—now including SGLT2 inhibitors, which trials like CREDENCE and canagliflozin biomarker studies show also lower NT-proBNP—can be cost-effective, but the calculations depend heavily on local drug prices, laboratory costs, and the structure of primary care. The review’s authors argue that health technology assessment should be built into program design from the outset rather than retrofitted after launch.

The stakes are enormous. The International Diabetes Federation’s latest atlas estimates that well over half a billion adults live with diabetes, a number projected to climb steeply, and each of those individuals carries a markedly elevated risk of progressing to heart failure. Because early identification and management demonstrably improve outcomes, the gap between guideline recommendations and universal practice represents preventable morbidity and death on a global scale. The review’s central message is one of cautious optimism: the biomarker exists, the trials support screening, the guidelines endorse it, and national consensus documents are accumulating. What remains is the unglamorous but decisive work of building pathways, training clinicians, aligning resources, and proving value—so that a routine blood draw at a diabetes check-up becomes, everywhere, an early warning system for the heart.

Subject of Research: Implementation of NT-proBNP biomarker testing for early detection of heart failure in people with diabetes

Article Title: Translating Guidelines into Practice: Implementation of NT-proBNP Testing for Early Heart Failure Detection in Diabetes, a Narrative Review

Article References: Pop-Busui, R., Cebrián-Cuenca, A., Ceponis, J., Da Porto, A., dos Santos, J., Gavina, C., Gastaldi, G., Janež, A., Joshi, A., McDonald, K., Meyer, G., Rotar Pavlič, D., Ükinç, K., & Januzzi, J. L. (2026). Translating Guidelines into Practice: Implementation of NT-proBNP Testing for Early Heart Failure Detection in Diabetes, a Narrative Review. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10791-y

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10791-y

Keywords: NT-proBNP, heart failure, diabetes, Stage B heart failure, biomarker screening, American Diabetes Association guidelines, cardiovascular risk, early detection, implementation, cost-effectiveness, narrative review, cardiometabolic medicine

The scale of the problem is growing as populations age and the prevalence of obesity, hypertension, diabetes and chronic kidney disease rises. In the United States, total medical costs associated with heart failure are projected to exceed $70 billion by 2030. The condition already affects approximately 22 percent of people with type 2 diabetes—more than one in five patients. Diabetes itself is considered stage A heart failure under the contemporary staging system, meaning that it places a person at increased risk even in the absence of symptoms or detectable structural heart disease. That risk is amplified by high blood pressure, excess adiposity, coronary disease, smoking and impaired kidney function. The experts describe these conditions not as isolated diagnoses but as interconnected components of cardiovascular-kidney-metabolic syndrome, in which disturbances in glucose regulation, vascular biology, renal filtration and cardiac function reinforce one another.

Heart failure is not a single mechanical failure in which the heart simply stops pumping. It is a clinical syndrome in which the heart cannot meet the body’s demands without elevated filling pressures, leading to symptoms, fluid accumulation and progressive organ dysfunction. The disease is divided into stages that describe its evolution. Stage A includes people at risk, including those with type 2 diabetes but no symptoms. Stage B, often called pre-heart failure, refers to people who have structural or functional abnormalities of the heart or abnormal cardiac biomarkers without symptoms. Stage C is symptomatic heart failure, while stage D represents advanced disease, in which symptoms interfere with daily activities and hospitalizations may occur repeatedly. By the time a patient reports shortness of breath, ankle swelling or obvious congestion, the disease may already have crossed into stage C.

The clinical challenge is that early heart failure can look remarkably ordinary. Fatigue, reduced exercise capacity, breathlessness and swelling can be attributed to aging, obesity, chronic obstructive pulmonary disease, venous insufficiency, kidney disease or deconditioning. In people with multiple medical conditions, clinicians may have difficulty identifying which diagnosis is driving a change in symptoms. Heart failure is consequently missed or misdiagnosed, particularly in patients who also have lung disease or ischemic heart disease. An apparently simple complaint such as leg edema can reflect increased venous pressure caused by cardiac dysfunction, but it can also arise from cirrhosis, nephrotic syndrome, thyroid disease or chronic venous disease. The commentary argues that the first safeguard is a deliberate medical history and physical examination that treats these symptoms as possible clues to cardiac disease rather than automatically assigning them to a familiar comorbidity.

The authors also emphasize that heart failure associated with diabetes frequently occurs even when the heart’s pumping percentage appears normal. Clinicians classify heart failure partly by left ventricular ejection fraction, the proportion of blood expelled from the main pumping chamber with each contraction. Heart failure with reduced ejection fraction, or HFrEF, is defined by an ejection fraction of 40 percent or less. Heart failure with preserved ejection fraction, or HFpEF, generally involves an ejection fraction of at least 50 percent, while values between 40 and 50 percent fall into an intermediate category. In HFpEF, the ventricle may contract sufficiently but become stiff, preventing it from relaxing and filling normally. The resulting rise in pressure can force fluid backward into the lungs and tissues. Diabetes, obesity, hypertension and kidney disease are strongly associated with this form of heart failure, meaning that a “normal” ejection fraction does not rule out serious cardiac dysfunction.

For patients at elevated risk, the experts highlight blood tests that can reveal cardiac stress before severe symptoms develop. Natriuretic peptides—principally B-type natriuretic peptide, or BNP, and its inactive precursor N-terminal pro-BNP, or NT-proBNP—are released when the heart muscle is stretched by pressure or volume overload. BNP is produced from a precursor molecule and acts hormonally, promoting the excretion of sodium and water and encouraging blood-vessel relaxation; NT-proBNP is biologically inactive but remains useful because its concentration reflects the same underlying stress. The commentary identifies BNP levels above 50 picograms per milliliter and NT-proBNP levels above 125 picograms per milliliter as useful risk thresholds, while high-sensitivity cardiac troponin above the 99th percentile for a healthy population may indicate myocardial injury or stress. The authors recommend at least annual measurement of a natriuretic peptide or high-sensitivity troponin in high-risk patients, with more frequent testing when clinical status changes.

These biomarkers are not crystal balls, and their interpretation requires physiological context. NT-proBNP and BNP can rise with age, atrial fibrillation and chronic kidney disease even when worsening heart failure is not the immediate cause. Reduced kidney filtration slows the removal of circulating molecules and reflects broader changes in fluid balance and vascular health. Conversely, obesity can suppress natriuretic peptide concentrations, potentially masking significant cardiac dysfunction and producing a deceptively reassuring result. For that reason, the experts caution against treating a single laboratory value as a diagnosis. Trends may be more informative than isolated measurements. In the EXAMINE trial, which included people with type 2 diabetes, two NT-proBNP measurements taken six months apart helped distinguish risk: patients with persistently elevated values had the greatest likelihood of developing heart failure, while an increase from baseline was itself associated with rising risk. Serial testing effectively turns a snapshot into a trajectory.

When biomarkers or symptoms raise concern, echocardiography is the next important investigation. An echocardiogram uses ultrasound waves to generate moving images of the heart, allowing clinicians to assess chamber size, wall motion, valve function, filling patterns and pumping performance. It can reveal structural remodeling caused by long-standing hypertension, evidence of prior ischemic injury or abnormalities consistent with diabetic cardiomyopathy. It also helps distinguish HFrEF from HFpEF and can identify conditions that require different treatment strategies. The clinicians do not recommend echocardiography for every person with diabetes solely because diabetes confers risk. Rather, they describe a targeted sequence: identify high-risk patients, examine them carefully, measure biomarkers and arrange imaging when results or clinical findings suggest cardiac dysfunction. Importantly, they stress that potentially beneficial intervention should not necessarily be postponed while waiting for an echocardiogram, particularly when the overall clinical picture is compelling.

Risk-prediction tools such as the TIMI Heart Failure Risk Score and the Health ABC Heart Failure Risk Model may help clinicians understand how age, diabetes, hypertension and other variables combine to influence prognosis, but the specialists present them as aids rather than replacements for clinical judgment. The most urgent opportunity lies in the period before repeated decompensations, emergency visits and hospital admissions begin. Heart failure often has an initially stable phase followed by episodes in which fluid accumulates, symptoms worsen and the risk of hospitalization and death rises. Earlier recognition can lengthen the period of relative stability and preserve quality of life. The commentary therefore calls for a coordinated approach in which primary-care practices and diabetes clinics participate directly in cardiovascular surveillance. Patient conversations should explain why heart failure is being assessed, while prevention efforts address weight management, smoking cessation, physical activity and adherence to prescribed medication. The podcast’s later episodes are intended to discuss guideline-directed drug therapy and lifestyle modification, but the first episode’s message is that detection is the gateway to every subsequent intervention.

The experts’ appeal reflects a broader shift in cardiovascular medicine: diabetes care can no longer focus only on blood glucose, retinal disease, neuropathy and atherosclerotic events while treating heart failure as a specialist problem. The biological links between insulin resistance, inflammation, adipose-tissue dysfunction, arterial stiffening, renal injury and myocardial remodeling make heart failure a core complication of metabolic disease. A patient who appears stable in an endocrinology or primary-care waiting room may already have stage B disease, with changes that are detectable through biomarkers or imaging but not yet severe enough to cause obvious symptoms. Recognizing that hidden phase could be decisive, because treatment and risk-factor control are more likely to prevent deterioration before the heart enters a cycle of congestion and hospitalization. The commentary, developed by Desai, Inzucchi and Wright as the first installment of a clinical podcast series, does not report a new clinical trial or newly generated dataset. Instead, it translates existing evidence into an urgent clinical signal: in people with diabetes, the search for heart failure should begin before the heart failure announces itself.